Deborah Harland
SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested over $680 million in the biotech space and has a current portfolio of approximately 30 private and public companies. For more information, visit www.srone.com
SR One
General Partner
Dr Raul Insa
SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new therapeutic indications for given drugs, which we are offering to partners for expanding their drug pipeline.
During the last 34 months we have validated 41 new indications, with 18 positive hits (43%), of which 3 cover clear medical need indications:
SOM0777 for the treatment of Glioma, already licensed to Argon Pharma and Draconis Pharma.
SOM0226 for the treatment of TTR-Amyloidosis. Orphan Disease. Phase II planned for 1Q 2013.
SOM0606 for the topical treatment of Psoriasis, in preclinical development. Phase II expected for 4Q 2013.
25 more repurposing programs per year are running to file the advanced company pipeline.
SOM Biotech
CEO
